At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 97 enrolled
Drug / intervention
DMXB-A-SR +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Nicotinic Receptors and Schizophrenia: Phase II
In Brief
A Phase 2 clinical trial evaluating DMXB-A-SR and Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 97 participants across 2 sites.
Detailed Summary
The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia who are smokers and who are non-smokers. The study drug may also maintain abstinence from cigarette smoking and improve other symptoms in patients with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionJun 2015
TodayJul 2026
First PostedJul 22, 2011
Enrollment StartJul 1, 2011
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 14.9 years ago
Interventions
DMXB-A-SRdrug
Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
Placeboother
Placebo Comparator